Choosing Wisely: Which Patients Benefit Most Clinicians often meet patients carrying different goals: metabolic control, weight reduction, or glycemic stability
It is important to recognise that QALY thresholds should consider active case finding in individuals under 35, as steatotic liver disease, including MASH, increasingly affects younger populations
GLP-1 medications are helping many people move the scale
The physical transformation is the easy part
As industry leaders and sales executives, it's imperative to stay informed of these advancements, comprehend their implications, and harness their capabilities to enhance patient care
Semaglutide prices can drop as low as $25 per month with coverage, but they rise to $350 (or more) without